Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Fulltext:
69689.pdf
Embargo:
until further notice
Size:
133.5Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2008Source
Journal of Clinical Oncology, 26, 31, (2008), pp. 5094-100ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Biochemistry (UMC)
Haematology
CHL
Former Organization
Radboud University Nijmegen Medical Centre
Journal title
Journal of Clinical Oncology
Volume
vol. 26
Issue
iss. 31
Page start
p. 5094
Page end
p. 100
Subject
IGMD 7: Iron metabolism; NCMLS 1: Immunity, infection and tissue repair; NCMLS 2: Immune Regulation; ONCOL 3: Translational research; UMCN 1.4: Immunotherapy, gene therapy and transplantationAbstract
PURPOSE: Patients with chronic lymphocytic leukemia (CLL) and 17p deletion (17p-) have a poor prognosis. Although allogeneic hematopoietic stem-cell transplantation (HCT) has the potential to cure patients with advanced CLL, it is not known whether this holds true for patients with 17p-CLL. PATIENTS AND METHODS: Baseline data from patients, for whom information on the presence of 17p-CLL was available, were downloaded from the European Group for Blood and Marrow Transplantation database. Additional information on the course of CLL and follow-up was collected with a questionnaire. RESULTS: A total of 44 patients with 17p-CLL received allogeneic HCT between March 1995 and July 2006 from a matched sibling (n = 24) or an alternative donor (n = 20). 17p-CLL had been diagnosed by fluorescent in situ hybridization in 82% of patients and by conventional banding in 18% of patients. The median age was 54 years. Before HCT, a median of three lines of chemotherapy had been administered. At HCT, 53% of patients were in remission. Reduced-intensity conditioning was applied in 89% of patients. Acute, grade 2 to 4 graft-versus-host disease (GVHD) occurred in 43% of patients, and extensive chronic GVHD occurred in 53% of patients. At last follow-up, 19 patients were alive, with a median observation time of 39 months (range, 18 to 101 months). Three-year overall survival and progression-free survival rates were 44% and 37%, respectively. The cumulative incidence of progressive disease at 4 years was 34%. No late relapse occurred in nine patients with a follow-up longer than 4 years. CONCLUSION: Allogeneic HCT has the potential to induce long-term disease-free survival in patients with 17p-CLL.
This item appears in the following Collection(s)
- Academic publications [238441]
- Electronic publications [122544]
- Faculty of Medical Sciences [90373]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.